Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06182072 | ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07199127 |
| Duodenal Polyposis Classification in FAP(DRACO) |
| recruiting |
| — |
| 300 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER |
| 1 |
| Sep 30, 2025 |
| clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05988645 | Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) | recruiting | N/A | 50 | MiWEndo Solutions S.L.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | recruiting | Phase 2 | 33 | Yongyi ZengOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06467799 | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05186116 | LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis(LIVERMORE) | recruiting | N/A | 25 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05808634 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. | recruiting | Phase 1 | 168 | BioAtla, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05971108 | Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC(REVISE-HCC) | recruiting | N/A | 600 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06708910 | AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI | recruiting | — | 460 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma(CABOLD) | recruiting | Phase 4 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07190638 | Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial(CORTEX) | recruiting | N/A | 80 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06087120 | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment(BRAVA) | recruiting | — | 125 | Gene SolutionsINDUSTRY | 2 | Sep 23, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07045935 | Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment(ProBOLIC) | recruiting | Phase 4 | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06658782 | Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer(AMULET) | recruiting | — | 300 | University of OxfordOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186010 | Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy | recruiting | — | 50 | Asan Medical CenterOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | recruiting | Phase 3 | 286 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04525833 | Liver Disease and Other Systemic Diseases | recruiting | — | 15,000 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05795101 | TRUDI: TDXD+Durva in HER2+/Low IBC(TRUDI) | recruiting | Phase 2 | 63 | Filipa Lynce, MDOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07095114 | A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. | recruiting | N/A | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07179783 | Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) | recruiting | Phase 2 | 28 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07178093 | Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization | recruiting | N/A | 60 | Taichung Tzu Chi HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04794322 | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer | recruiting | — | 250 | Massachusetts General HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06831461 | Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors(PRIDE) | recruiting | N/A | 156 | Tata Memorial CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | recruiting | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07175480 | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk(Perfumer) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04665687 | Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients | recruiting | — | 1,730 | Samsung Medical CenterOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07170345 | Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion(HCC-MVI-CAD) | recruiting | — | 400 | Chinese Academy of SciencesOTHER_GOV | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | recruiting | Phase 2 | 520 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04159142 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | recruiting | Phase 2 | 414 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05998135 | Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07167329 | Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial(BELIEVE-VHL) | recruiting | Phase 2 | 100 | José Claudio Casali da RochaOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06179602 | Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors(A-IMAGIO) | recruiting | — | 1,500 | Leiden University Medical CenterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06831136 | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma(PANCARDINAL-2) | recruiting | Phase 2 | 24 | The University of Texas Health Science Center, HoustonOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06999694 | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Proton-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07102901 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 351 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07166445 | Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT | recruiting | — | 1,000 | Peking University First HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05600400 | Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer(iSMART) | recruiting | N/A | 144 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 9, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Oct 1, 2025source: clinicaltrials